Literature DB >> 7352572

CSF monoamine metabolites in depression and schizophrenia.

P A Berger, K F Faull, J Kilkowski, P J Anderson, H Kraemer, K L Davis, J D Barchas.   

Abstract

The authors report cerebrospinal fluid (CSF) concentrations of five monoamine metabolites before and after probenecid administration in normal subjects and patients with depression and schizophrenia. No differences were found in baseline metabolite concentrations among the three groups. CSF metabolite and CSF probenecid concentrations were significantly correlated in depressed patients for all metabolites, and there was decreased postprobenecid accumulation of homovanillic acid in the CSF of depressed patients compared with schizophrenic patients and with normal subjects. The authors propose a method for correcting for probenecid concentrations. Data from normal subjects should be of value for other investigators using the probenecid technique.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7352572     DOI: 10.1176/ajp.137.2.174

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  14 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

2.  Determinations of 5-hydroxyindoleacetic acid and homovanillic acid in human CSF with monitoring of probenecid levels in CSF and plasma.

Authors:  B M Emanuelsson; E Widerlöv; H Walléus; L K Paalzow
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Decrease in plasma levels of 3,4-dihydroxyphenylethyleneglycol in major depression.

Authors:  B Scatton; H Loo; T Dennis; C Benkelfat; C Gay; M F Poirier-Littre
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  N-acetylaspartic acid (NAA) and N-acetylaspartylglutamic acid (NAAG) in human ventricular, subarachnoid, and lumbar cerebrospinal fluid.

Authors:  K F Faull; R Rafie; N Pascoe; L Marsh; A Pfefferbaum
Journal:  Neurochem Res       Date:  1999-10       Impact factor: 3.996

5.  Current perspectives on incentive salience and applications to clinical disorders.

Authors:  Jeffrey J Olney; Shelley M Warlow; Erin E Naffziger; Kent C Berridge
Journal:  Curr Opin Behav Sci       Date:  2018-01-30

6.  Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.

Authors:  K Baraczka; M I Fekete; B Kanyicska
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

7.  Correlation of individual symptoms and other clinical variables with cerebrospinal fluid amine metabolites and tryptophan in depression.

Authors:  C M Banki; G Molnar; I Fekete
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1981

8.  Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence.

Authors:  C M Banki
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

Review 9.  Dopamine and depression.

Authors:  A S Brown; S Gershon
Journal:  J Neural Transm Gen Sect       Date:  1993

10.  5-hydroxytryptamine and depression: a model for the interaction of normal variance with pathology.

Authors:  F K Goodwin; R M Post
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.